Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a single institution phase II study that will enroll patients with T0-3N0-2 p16-positive oropharyngeal squamous cell carcinoma (OSCC) undergoing resection of all gross visible disease at the primary site and in the lymph nodes.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rak płaskonabłonkowy gardła związany z wirusem HPV (potwierdzone badaniami)
- •Guz o rozmiarze T0-3 i zaangażowaniem węzłów chłonnych N0-2
- •Całkowite chirurgiczne usunięcie wszystkich widocznych zmian nowotworowych
- •Wykonana operacja węzłów chłonnych na szyi
- •Obecność co najmniej jednego czynnika ryzyka (duży guz, wiele zajętych węzłów, rozległa inwazja)
- •Dla pacjentów zgłoszonych przed operacją: wykrywalny DNA wirusa HPV w badaniu krwi
- •Wiek co najmniej 18 lat
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 5, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (4)
Cedars-Sinai Cancer at Beverly Hills (THO)
Beverly Hills, United States
Cedars Sinai Medical Center
Los Angeles, United States
CS Cancer at Valley Oncology Medical Group
Tarzana, United States
CS Cancer at the Hunt Cancer Center
Torrance, United States
Trial contact
Clinical Trial Navigator
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/6/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.